Crescent Biopharma, Inc.
Crescent Biopharma, Inc. (CBIO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cbio · stock forecast · 13 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 13 Wall Street analysts in the past 3 months
Buy
13 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$35.00
Consensus
$33.00
+91.0% upside
Low
$29.00
Median: $35 · Last Close: $17.28
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$33.00
91.0% upside
High Target
$35
102.5%
Low Target
$29
67.8%
Current Price
$17.28
as of today
Based on analyst price targets, the CBIO stock price prediction for the next 12 months ranges from $29 to $35. The consensus CBIO price forecast of $33.00 implies 91.0% upside from the current price of $17.28.
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $16.45 | ↓ 4.82% |
1-day model range: $15.97–$16.92. Peak: $16.92 (-4.82%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -63.8% |
| 2029 | — | -69.2% |
| 2030 | — | -71.8% |
| 2031 | — | -73.1% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · CBIO · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-01 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2026-03-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-27 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-07-26 | TD Cowen | Downgrade ↓ | Buy→Hold |
| 2024-05-06 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2024-03-27 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-08-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-05-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-03-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-02-16 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Crescent Biopharma, Inc. (CBIO) stock. Of the recent 34 rating actions, 1 were upgrades and 7 were downgrades. 13 analysts currently cover CBIO.
Analyst Recommendation Trends
CBIO analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$2M
↓ 77.8% YoY
Revenue Next Year
$6M
↑ 206.4% YoY
EPS This Year
$-3.20
EPS Next Year
$-3.25
↑ 1.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast CBIO EPS of $-3.20 for the current fiscal year, based on estimates from 5 analysts. The CBIO revenue forecast is $2M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CBIO stock forecast is supported by two independent data sources: analyst consensus ratings from 13 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CBIO price target is $33.00 (+91.0% upside), with an analyst consensus of Buy.
The CBIO short-term stock prediction for tomorrow is $16.45 (-4.82%). The CBIO stock prediction for 2030 projects a range of $4–$6.
Crescent Biopharma, Inc. trades on NASDAQ under the ticker CBIO. The CBIO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 62% of covering analysts.
Frequently asked questions
CBIO forecast · 8 questionsAccording to 13 Wall Street analysts, the average 12-month CBIO price target is $33.00, with a high forecast of $35.00 and a low of $29.00. The median price target is shown in the chart above when available. This implies +91.0% potential upside from the current price of $17.28.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.